As part of its ongoing mission to provide comprehensive business and financial management solutions in support of clinical trials, Clinical Financial Services (CFS) is pleased to announce the launch of its newest offering, Site Activation Services. This new service, which includes regulatory document collection and management as well as global investigator budget and contract management, will streamline and automate the trial activation process and minimize financial risk for clinical trial sponsors, CROs, and investigative sites.
Headed by a team dedicated to managing the complex tasks required to activate investigator sites, CFS can accelerate clinical trial cycle times by maximizing the number of sites that are activated and "enrollment ready" when the enrollment phase of the trial begins.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.